CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells
CD40-CD40L interaction is crucial for the interplay between B and T cells and determines B-cell fate. Here, we investigated the effects of CD40-CD40L inhibition on B-cell subsets and cytokine production using the non-depleting monoclonal anti-CD40 antibody CFZ534. CFZ534 had no impact on B-cell viability but inhibited TLR9-agonistic (CpG-ODN) CD40L- as well as CD40L-mediated proliferation. The plasmablast subset was reduced after stimulation with CpG-ODN + CD40L, but this effect was completely restored by CFZ534-mediated CD40 blockade. IgG as well as IgM-secreting cells were significantly reduced in the presence of CFZ534 upon CD40L stimulation. CpG-ODN, but not CD40L, induced Granzyme B production in B cells after CD40-blockade and CpG-ODN/CD40L stimulation. Moreover, we found that IL-10 and Granzyme B were produced by separate B-cell subsets. Hence, CD40-blockade mediated by CFZ534 increased Granzyme B production and decreased IL-10 production in CD24hiCD38hi B cells with a transitional phenotype and led to a significant decrease in the expression of the pro-inflammatory cytokines IL-6, IL-12p35, and IL-23p19 and TNFα in a B and CD4 + TH-cell co-culture system. Based on these preclinical results, CD40 blockade by the Fc-silent, non-depleting monoclonal antibody CFZ534 exerts an anti-inflammatory effect on B cells, including hampering the IgG class switch without affecting their viability.
Authors
- Catherine H. Régnier (ORCID: https://orcid.org/0000-0002-4386-1324)
- Felix Werner (ORCID: https://orcid.org/0000-0003-1906-5157)
- Ida Allabauer
- Wolfgang Schuh
- Mandy Wahlbuhl (ORCID: https://orcid.org/0000-0003-0523-6760)
- B. Dietel-Schor
- Alexander Schnell (ORCID: https://orcid.org/0000-0002-2734-7181)
- Holger Hackstein (ORCID: https://orcid.org/0000-0001-9722-8180)
- James S. Rush (ORCID: https://orcid.org/0000-0001-5846-448X)
- Hans‐Martin Jäck (ORCID: https://orcid.org/0000-0002-6332-8463)
- Christian H.K. Lehmann (ORCID: https://orcid.org/0000-0001-5927-9761)
- Adrian Hoffmann (ORCID: https://orcid.org/0009-0000-0661-2321)
- Jens Wittner (ORCID: https://orcid.org/0000-0002-9729-9111)
- André Hoerning (ORCID: https://orcid.org/0000-0001-6241-7168)
- Joachim Woelfle (ORCID: https://orcid.org/0000-0002-9132-6174)
- Tobias Krickau (ORCID: https://orcid.org/0009-0002-2675-7610)
Institutions
- Novartis (Switzerland) (CH)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University Medical Center Freiburg (DE)
- Universitätsklinikum Erlangen (DE)
- Integrated BioTherapeutics (United States) (US)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- Clinical & Experimental Immunology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/cei/uxaf044
- Citations
- 1
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.80